Y Intercept Hong Kong Ltd Acquires Shares of 1,055,367 Kenvue Inc. $KVUE

Key Points

• Y Intercept Hong Kong Ltd. acquired 1,055,367 Kenvue shares worth approximately $20.2 million, representing about 0.05% of the company and 0.4% of the investor’s portfolio.
• Kenvue’s latest quarterly results slightly missed expectations, with EPS of $0.31 versus $0.32 expected and revenue of $3.96 billion; revenue still grew 3% year over year.
• The stock traded near $18.97, while analysts maintained a predominantly “Hold” consensus with an average price target of $19.27. Kenvue offers a quarterly dividend of $0.21, or an annualized yield of about 4.4%.

Y Intercept Hong Kong Ltd bought a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,055,367 shares of the company's stock, valued at approximately $20,168,000. Kenvue accounts for 0.4% of Y Intercept Hong Kong Ltd's investment portfolio, making the stock its 29th biggest position. Y Intercept Hong Kong Ltd owned about 0.05% of Kenvue at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of KVUE. CoreCap Advisors LLC grew its stake in Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock valued at $29,000 after buying an additional 591 shares in the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Kenvue during the fourth quarter worth $26,000. Physician Wealth Advisors Inc. boosted its holdings in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after acquiring an additional 618 shares during the period. MV Capital Management Inc. bought a new position in shares of Kenvue in the fourth quarter worth $28,000. Finally, Reflection Asset Management purchased a new position in shares of Kenvue in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

NYSE:KVUE opened at $18.97 on Thursday. The firm has a market capitalization of $36.44 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.36 and a beta of 0.47. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $21.95. The stock has a fifty day moving average of $18.88 and a 200 day moving average of $18.12. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.01). The business had revenue of $3.96 billion during the quarter, compared to analysts' expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business's revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.29 EPS. On average, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue's dividend payout ratio (DPR) is currently 95.40%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Citigroup decreased their price objective on Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 15th. Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of Kenvue from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Finally, Zacks Research cut shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source